Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

This symposium, ‘A case-based approach to navigating treatment switch in late-onset Pompe Disease (LOPD)’, was held at the ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...